IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Klaus Schlossmann

USPTO Granted Patents = 11

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 53(Granted Patents)


Company Filing History:

goldMedal11 out of 12,157 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1979-1991

Loading Chart...
11 patents (USPTO):Explore Patents
1. 5026714 - Novel 1-alkyl-substituted 1,4-dihydropyridinelactone anti-diabetics (1991-06-25),
2. 4976964 - Medicament formulation containing dihydropyridines and a process for its (1990-12-11),
3. 4894378 - Lowering blood sugar with novel 4-thienyl-dihydropyridines (1990-01-16),
4. 4801715 - Certain 4-thienyl-dihydropyridines (1989-01-31),
5. 4786641 - Dihydropyridine compounds and their use in reducing blood sugar (1988-11-22),
6. 4721719 - Dihydropyridinelactols and their use as medicaments which influence (1988-01-26),
7. 4670460 - Inhibiting lipoxygenase with pyrazolone derivatives (1987-06-02),
8. 4657924 - Nafazatrom as a lipoxygenase inhibitor (1987-04-14),
9. 4540707 - Nafazatrom as a lipoxygenase inhibitor (1985-09-10),
10. 4188395 - 1,4-Dihydropyridine derivatives substituted in the 2 position, and their (1980-02-12),
11. 4177278 - 2-Alkyleneaminodihydropyridines compounds, their production and their (1979-12-04),

Title: Klaus Schlossmann: Innovator in Anti-Diabetic Medications

Introduction

Klaus Schlossmann is a prominent inventor based in Wuppertal, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-diabetic medications. With a total of 11 patents to his name, Schlossmann's work has had a substantial impact on medical science.

Latest Patents

Among his latest patents are innovative formulations of 1-alkyl-substituted 1,4-dihydropyridinelactones, which serve as effective anti-diabetic agents. These compounds are designed to lower blood sugar levels and include various substituents such as halogen, alkyl, and alkoxy groups. Another notable patent involves a medicament formulation that enhances the parenteral administration of dihydropyridines, utilizing liposomes to improve drug delivery.

Career Highlights

Klaus Schlossmann has dedicated his career to advancing pharmaceutical research and development. His work at Bayer Aktiengesellschaft has positioned him as a key figure in the industry, where he continues to innovate and contribute to the field of diabetes treatment.

Collaborations

Throughout his career, Schlossmann has collaborated with esteemed colleagues such as Siegfried Goldmann and Walter Puls. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

Klaus Schlossmann's contributions to the field of anti-diabetic medications exemplify his dedication to improving healthcare through innovation. His numerous patents and ongoing work at Bayer Aktiengesellschaft highlight his role as a leading inventor in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…